Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Reactivation of HIV-1 Gene Expression to Treat Persistent HIV Infection
Université Libre de Bruxelles Belgium flag Belgium
Abstract ID:
The combined use of two drugs to activate latent HIV could cause a synergistic reactivation of HIV-1 production. Indeed, a proof-of-concept has been demonstrated by inventors for the coadministration of two different types of therapeutically promising HIV...
Contact
Participants
You
Email me a copy of this message

STATE OF THE ART

Despite current effective and life-prolonging cART, HIV-1 can still not be cured. Indeed, the persistence of latently-infected resting CD4+ T cells harboring transcriptionally silent but replication competent HIV-1 proviruses seriously challenge the hope of HIV-1 eradication from cART-treated HIV-1 infected patients. Reactivation of HIV-1 expression in reservoirs together with an efficient cART has been proposed as an adjuvant therapy aimed at reaching a functional cure.

Several studies have identified individual compounds that are capable of reversing HIV-1 latency and several clinical trials have started. However, these studies question the efficiency of these drugs used alone and underly the importance to further test other classes of HIV-1 inducers, alone or in combination, to reduce the HIV-1 reservoirs.

THE INVENTION

The combined use of two drugs to activate latent HIV could cause a synergistic reactivation of HIV-1 production. Indeed, a proof-of-concept has been demonstrated by inventors for the coadministration of two different types of therapeutically promising HIV-1 inducers [DNA methylation inhibitors in combination with histone deacethylase inhibitors (HDACis) or histone methyltransferase inhibitors (HMTis) in combination with HDACi or NF-kappaB inducers] together with efficient cART as a therapeutic perspective to decrease the pool of latent HIV-1 reservoirs.

COMMERCIAL INTEREST

As selected molecules are already promising candidates or accepted in human clinical trials or therapies for other diseases, a clinical phase Ib/II has been launched. The cART therapy is the only treatment currently available for AIDS and our current approach is innovative, no competition exists for the moment in this competitive market.

KEY ADVANTAGES OF THE TECHNOLOGY

Obtaining a regimen to eliminate the latent compartment of HIV-1 and stop cART therapies may:

limit exposure to the anti-AIDS molecules, thereby limiting side effects

the life quality of the patients would be greatly improved.

reduce the care costs for HIV+ patients.

MAIN PUBLICATIONS (related to this technology)

- Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1+ HAART-treated patients. Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, de Wit S, Clumeck N, Lambotte O, Rouzioux C, Rohr O, Van Lint C - Aids 2012, 26:1473-82. IF : 6,245

- HIV-1 transcription and latency: an update. Van Lint C, Bouchat S, Marcello A. Retrovirology 2013, 10: 67. IF: 5,660

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
WO2013050422
FEATURED
Last Updated May 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
UNIVERSITY